After the Supreme Court of Canada (SCC) held that AstraZeneca’s patent relating to esomeprazole (NEXIUM) was not invalid for inutility and the SCC’s dismissal of Apotex’s post-judgment motion for reconsideration and rehearing, Apotex sought to raise new grounds of patent invalidity in the Federal Court, premised on “overpromising” under insufficiency, wilful misleading and overbreadth. Justice Locke dismissed Apotex’s motion (AstraZeneca v Apotex, 2018 FC 185): the validity of the patent was finally decided by the SCC; any doubt that might have remained about the SCC’s intent was resolved by the SCC’s dismissal of Apotex’s motion. Justice Locke also held that AstraZeneca was entitled to a declaration of infringement and ordered the quantification of AstraZeneca’s damages or Apotex’s profits. Apotex has appealed.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More -
2025 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.Read More